GEMINI-1 and -2: DTG + 3TC Noninferior to DTG + FTC/TDF at Wk 96 in ART-Naive Adults

July 21-24, 2019; Mexico City, Mexico
In prespecified secondary analyses, HIV-1 RNA < 50 copies/mL achieved by 86.0% of patients receiving dual therapy vs 89.5% receiving triple-drug ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 279 KB
Released: July 24, 2019

Acknowledgements

Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Dr Joseph Eron and Clinical Care Options (CCO): Weight gain in initial ART, GEMINI, ADVANCE trials, and more

Joseph J. Eron, Jr., MD Released: July 22, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

At Week 124, 80% of patients maintained virologic suppression on monthly cabotegravir + rilpivirine, with no new safety signals since Week 96, reported by Clinical Care Options (CCO) from IAS 2021.

Released: July 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue